BNET Industries
Last Fiscal Year Sales:$300.0M
- Private
- US
Dow Jones Description
We are a diagnostics business that delivers personalized disease management through a combination of products and services incorporating proprietary discoveries. We are organized into three reporting segments, a clinical laboratory testing service business (Lab Services), a products business (Products), and a segment that includes other activities under corporate management (Corporate). Our Lab Services business, conducted through Berkeley HeartLab, Inc. (BHL), offers a broad portfolio of clinical laboratory tests and disease management services designed to help healthcare providers improve cardiovascular disease treatment regimens for patients. Our Products business develops, manufactures, and oversees the commercialization of molecular diagnostic products. Most of this business is conducted through distribution and royalty agreements with Abbott Molecular, a subsidiary of Abbott Laboratories. Our Corporate segment includes revenues from royalties, licenses, funded collaborations and milestones related to the licensing of certain intellectual property and from our former small molecule and proteomic programs.
Chairman, President and Chief Executive Officer
Tony L. WhiteNumber of Employees 749
Contact Information
1401 Harbor Bay Pkwy
Alameda, California 94502-7070
1 510 749 1853
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
News & Analysis
Filter by
celera genomics - All News and Analysis
23andMe's Price Cut: The End of Commerical Personal Genomics?
A huge price cut by personal-genomics pioneer 23andMe may well herald the demise of the commercial personal-genomics business before it even really got started -- and for much the same reason that startups such as Celera Genomics saw their genome-based information businesses crash and burn almost a decade ago. by...
Genomic information and the public-private imbalance
This paper investigates the extent to which public-private relationships produce unbalancing effects in the case of the generation and use of genomic/genetic information. To this end, it focuses on two interconnected issues. The first is the purported importance of genomic information, which is used to justify public spending on its...
Veterinary Laboratories Agency, U.K. and Applied Biosystems to Commercialize New Avian Influenza and Newcastle Disease Detection Kits; New Avian influenza assays developed by VLA expected to expand upon the existing Applied Biosystems Avian Influenza A/H5
M2 PRESSWIRE-7 March 2007-Applied Biosystems: Veterinary Laboratories Agency, U.K. and Applied Biosystems to Commercialize New Avian Influenza and Newcastle Disease Detection Kits; New Avian influenza assays developed by VLA expected to expand upon the existing Applied Biosystems Avian Influenza A/H5 detection kitsC1994-2007 M2 COMMUNICATIONS LTD...
The 'evolution' of a PhD project—from jumping genes to biochemical pathways
In this essay, I describe how my PhD project 'evolved' from the study of jumping genes and regulation of a single gene, Cyp6g1, to the expressional characterisation of the entire family of genes of which Cyp6g1 is a member. Furthermore, I describe how an early single control experiment led to...
Applied Biosystems Announces Collaboration with Eagle Research and Development
Co-Development Work to Begin on Portable, Single Molecule Detection Device Capable of Rapid and Inexpensive Protein and DNA Analysis FOSTER CITY, Calif. -- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced that it has signed an agreement with Eagle Research and Development, LLC to collaborate on further...
Celera Genomics Group of Rockville reports net loss of $7.1 million
Celera Genomics Group, of Rockville, a drug discovery company, reported a net loss of $7.1 million, or 9 cents per diluted share, for its fiscal first quarter ended Sept. 30, compared to a net loss of $16.7 million, or 23 cents per diluted share, for the first quarter of fiscal...
Celera Genomics Reports First Quarter Fiscal 2007 Results
ROCKVILLE, Md. -- Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $7.1 million, or $0.09 per share, for the first quarter of fiscal 2007 ended September 30, 2006, compared to a net loss of $16.7 million, or $0.23 per share, for the first quarter...
Laboratory Productivity Improves with First Commercial Mass Spectrometry-based System for Amino Acid Analysis
Amino Acid 20/20 Analyzer from Applied Biosystems/MDS SCIEX Brings New Approach to Common Pharmaceutical, Food Testing, and Protein Research Applications FOSTER CITY, Calif. -- Applied Biosystems (NYSE: ABI), an Applera Corporation business, and its joint venture partner, MDS Sciex, a division of MDS Inc. (NYSE:MDZ, TSX:MDS), today announced a...
Applied Biosystems Group and Celera Genomics Group First Quarter Fiscal 2007 Financial Results and Conference Call Scheduled for October 25, 2006
NORWALK, Conn. -- Applera Corporation announced today that it will issue fiscal 2007 first quarter results for its Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) on Wednesday, October 25, 2006. Results are scheduled for release before the opening of trading on the New York Stock Exchange. Tony...
Validation Study Confirms Value of TaqMan® Drug Metabolism Genotyping Assays in Pharmacogenetic and Complex Disease Research
Reference Data Made Publicly Available Through SNP500Cancer and PharmGKB Web Sites FOSTER CITY, Calif. & NEW ORLEANS -- Today at the 56th annual meeting of the American Society of Human Genetics, scientists from Applied Biosystems (NYSE:ABI), an Applera Corporation business, and SAIC-Frederick, Inc. presented data showing that the TaqMan[R]...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Christopher Hall | Chief Business Officer |
| James Yee | Chief Scientific Officer |
| Joel R. Jung | Chief Financial Officer |
| Paulette Dillon | Chief Business |
| Peter Young | Chief Scientific Officer |
| Robert Booth | Chief Scientific Officer |
| Stacey R. Sias | Vice President & Chief Business Officer |
| Tom White | Cso & Vice President, Research |
| Ugo Deblasi | Chief Financial Officer |
| Kathy P. Ordonez | Senior Vice President, Applera and President, Celera Genomics and Celera Diagnostics |
| Barbara J. Kerr | Vice President, Human Resources |
| Michael A. Zoccoli | Vice President & Gm, Ivd Products Division |
| Michael J Green | Vice President, Chemistry |
| Paul D. Arata | Vice President, Human Resources and Administration |
| Scott K. Milsten | Vice President, General Counsel and Corporate Secretary |
| Victor K Lee | Senior Patent Attorney |
| Jean-Luc Belingard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Tony L. White | Chairman, President and Chief Executive Officer |
| Bennett M. Shapiro | Board of Directors |
| Gail K. Naughton | Board of Directors |
| Richard H. Ayers | Board of Directors |
| Wayne I. Roe | Board of Directors |
| William G Green | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Applied Biosystems Group | Chairman and Chief Executive Officer | Current |
| Applera Corporation | Chairman, President & CEO | Current |
| Celera Genomics | Chairman, President and Chief Executive Officer | Current |
| Celera Diagnostics, LLC | Current | |
| Centenary College | Board of Directors | Current |
| Ingersoll-Rand Company Limited | Director | Current |
| C.R. Bard, Inc. | Board of Directors | Current |
| Productivity Inc. | Director | Current |
| PerkinElmer, Inc. | Chief Executive Officer | Former |
| C.R. Bard, Inc. | Chairman, President and Chief Executive Officer, Applera Corporation | Former |
| PerkinElmer, Inc. | President | Former |
| Baxter International Inc. | Executive Vice President | Former |
| AT&T Inc. | Director | Former |
| AT&T Inc. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Business Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Scientific Officer | Current |
| Xdx, Inc. | Chief Medical Officer | Current |
| Roche Bioscience | Vice President, Clinical and Preclinical Research | Former |
| Syntex Corporation | Former | |
| University of California, Berkeley | Bachelor's Degree | Former |
Joel R. Jung, age 50, has served as our Chief Financial Officer since February 2008. Mr. Jung joined Applied Biosystems Celera group as Vice President of Finance in 2006. From 1995 to 2006, Mr. Jung held various management and finance positions with Chiron Corporation, an international manufacturer of biopharmaceuticals, vaccines, and blood testing products, including Vice President and Treasurer from 2003 to 2006.
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Business | Current |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Scientific Officer | Current |
| Genelabs Technologies, Inc. | Genelabs' Vice President, Biology | Current |
| Pfizer Inc. | Former | |
| GlaxoSmithKline Plc | Former | |
| University of Pennsylvania | Ph.D. In Molecular | Former |
| University of Oxford | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Scientific Officer | Current |
| Virobay Inc. | Board of Directors | Current |
| Hoffmann-La Roche Inc. | Former | |
| Roche Bioscience | Former | |
| University of London | PhD In Biochemistry | Former |
| University of London | BSc in Biochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Vice President & Chief Business Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Western Genomics | Chief Scientific Officer and Vice President of R&D for Western Genomics | Current |
| Celera Genomics | Cso & Vice President, Research | Current |
| Cetus Corporation | Former | |
| Roche Molecular Systems, Inc. | Former | |
| University of California, Berkeley | Ph.D. In Biochemistry | Former |
| The Johns Hopkins University | B.A. In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Applied Biosystems Group | President | Current |
| Celera Genomics Group | President | Current |
| Applera Corporation | Senior Vice President | Current |
| Celera Genomics | Senior Vice President, Applera and President, Celera Genomics and Celera Diagnostics | Current |
| Celera Genomics | CEO and Director | Current |
| Roche Molecular Systems, Inc. | Chief Executive Officer | Former |
| Applera Corporation | Chief Executive Officer | Former |
| Celera Genomics | President | Former |
| Applera Corporation | President | Former |
| Hoffmann-La Roche Inc. | President | Former |
| Roche Molecular Systems, Inc. | President | Former |
| Celera Genomics | President | Former |
| Celera Diagnostics, LLC | President | Former |
| Applied Biosystems Group | Senior Vice President, Applera Corporation, President, Celera Genomics and Celera Diagnostics | Former |
| Union Carbide Corporation | Former | |
| Roche | Former | |
| Applera Corporation | Chairman | Former |
| Hartwick College | Bachelor's Degree In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Applied Biosystems Group | Senior Vice President, Human Resources | Current |
| Celera Genomics | Vice President, Human Resources | Current |
| PerSeptive BioSystems, Inc. | Vice President, HR | Current |
| Applera Corporation | Vice President, Human Resources | Current |
| Celera Diagnostics, LLC | Current | |
| Applera Corporation | Board of Directors | Current |
| Chiron | Vice President, Human Resources | Former |
| Applied Biosystems Group | Vice President, Human Resources, Applera Corporation | Former |
| Applied Biosystems Group | Human Resources Executive | Former |
| Golden Gate University | Master’S of Business Aministration | Former |
| University of Rochester | Master’S of Education | Former |
| Wittenberg University | Bachelor’S Degree In American Studies | Former |
| Applera Corporation | Member | Former |
Michael A. Zoccoli , age 57, has served as our General Manager, Products Business since February 2008. He joined Applied Biosystems Celera group in January 2002, and held various positions, including Vice President of Development, Vice President of Development, Instruments Systems and Software, and Vice President of Development and Manufacturing, prior to being named to his current position. He previously worked in product development and project management at a number of companies, including Cetus Corporation, Roche Molecular Systems, Applied Imaging Corporation, and Bayer Diagnostics.
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Vice President & Gm, Ivd Products Division | Current |
| Celera Genomics | General Manager, Products Business | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Vice President, Chemistry | Current |
| Axys Pharmaceuticals | Former | |
| Schering-Plough Corporation | Former |
Paul D. Arata , age 53, has served as our Vice President of Human Resources and Administration since February 2008. Prior to joining Applied Biosystems Celera group, Mr. Arata held various human resources positions with Applied Biosystems from 2001 to 2008, most recently serving as Vice President of Human Resources and Site Services. Prior to joining Applied Biosystems, Mr. Arata held various human resources and administrative and management roles with Charles Schwab & Co., Inc., SBC Communications Inc. and Pacific Telesis Group.
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Vice President, Human Resources and Administration | Current |
| Site Services Inc. | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Vice President, General Counsel and Corporate Secretary | Current |
| Celera Genomics | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Western Genomics | Vice President and Chief Group Counsel | Current |
| Western Genomics | Senior Licensing Director | Current |
| Celera Genomics | Senior Patent Attorney | Current |
| Western Genomics | Patent Attorney | Current |
| Celera Genomics | Secretary | Current |
| Roche Molecular Systems, Inc. | Chief Patent Counsel | Former |
| University of Washington | Ph.D. In Experimental Pathology | Former |
| Brooklyn Law School | J.D. | Former |
| Eastern Washington University | Bachelor of Science | Former |
| Organization | Position | Status |
|---|---|---|
| Mind and Life Institute Co | Executive Vice President, Worldwide Licensing and | Current |
| Pure Tech Incorporated | Partner | Current |
| PureTech Ventures | Venture Partner | Current |
| Gelesis Inc. | Partner | Current |
| Protein Forest, Inc. | Venture Partner, Scientific Advisory Board Member and Board of Directors Member of Puretech Ventures | Current |
| Garrison Institute | Partner at Puretech Ventures | Current |
| The Harvard-MIT Division of Health Sciences and Technology | Advisory Committee Member | Current |
| Elixir Pharmaceuticals, Inc. | Board of Directors | Current |
| Elixir, LLC. | Board of Directors | Current |
| Mersana Therapeutics, Inc | Board of Directors | Current |
| Bg Medicine, Inc. | Board of Directors | Current |
| Mind and Life Institute Co | Board of Directors | Current |
| PureTech Ventures | Director | Current |
| Ikaria, Inc. | Board Member | Current |
| Momenta Pharmaceuticals, Inc. | Director | Current |
| Celera Genomics | Board of Directors | Current |
| Enlight Biosciences | Board of Directors | Current |
| Momenta.Com | Board of Directors | Current |
| Merck & Co. Inc. | Executive Vice President | Former |
| University of Washington | Professor | Former |
| Institut Pasteur | visiting scientist | Former |
| University of Washington | Chairman of the Department of Biochemistry | Former |
| Jefferson Medical College of Thomas Jefferson University | M.D. | Former |
| Dickinson College | B.S. In Chemistry | Former |
| Jefferson Medical College of Thomas Jefferson University | Degree In Medicine | Former |
Gail K. Naughton, age 52, has served as a director of Celera since July 2008. Dr. Naughton has been Dean of the College of Business Administration at San Diego State University since August 2002 and Chairman and Chief Executive Officer of Histogen, Inc., a regenerative medicine company, since June 2007. She was Vice Chairman of Advanced Tissue Sciences, Inc., a company involved in human-based tissue engineering, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000, and co-founder and director since inception in 1991. She is also a director of C.R. Bard, Inc. and SYS.
| Organization | Position | Status |
|---|---|---|
| Histogen, Inc. | Chief Executive Officer | Current |
| C.R. Bard, Inc. | Dean, College of Business Administration, San Diego State University | Current |
| San Diego State University | Dean | Current |
| Xsilogy, Inc. | Board of Directors, Chairman of Nominating and Compensation Committee | Current |
| Histogen, Inc. | Chairman | Current |
| SYS Technologies, Inc. | Director | Current |
| C.R. Bard, Inc. | Director | Current |
| Celera Genomics | Board of Directors | Current |
| Carmell Therapeutics Corporation | Board of Directors | Current |
| Advanced Tissue Sciences, Inc. | President | Former |
| Advanced Tissue Sciences, Inc. | Chief Operating Officer | Former |
| Advanced Tissue Sciences, Inc. | Co-Founder | Former |
| Advanced Tissue Sciences, Inc. | Vice Chairman | Former |
| University of California, Los Angeles | Mba | Former |
| San Diego State University | Business Administration | Former |
Jean-Luc Belingard (60) has served as a director of the Company since April 28, 1995. Mr. Belingard is Chairman and Chief Executive Officer of Ipsen SA, a diversified French health care holding company, and has served in that position since 2001. Prior to this position, Mr.
| Organization | Position | Status |
|---|---|---|
| Ipsen S.A. | Chief Executive Officer | Current |
| Ipsen S.A. | Chairman | Current |
| Laboratory Corporation of America Holdings | Board of Directors | Current |
| Celera Genomics | Director | Current |
| Applera Corporation | Director | Former |
Mr. Ayers is the retired Chairman and Chief Executive Officer of The Stanley Works, a tool and hardware manufacturer. He was an advisor to the Chairman and Chief Executive Officer of Stanley from January 1997 to October 1997 after having served as Chairman and Chief Executive Officer of Stanley from May 1989 to December 1996. Mr. Ayers is a Trustee of MassMutual Institutional Funds and MML Series Investment Fund and a director of Instron Corporation.
| Organization | Position | Status |
|---|---|---|
| Applera Corporation | Committee Member | Current |
| Celera Diagnostics, LLC | Current | |
| The Stanley Works | Chairman | Current |
| Instron Corporation | Director | Current |
| Applera Corporation | Director | Current |
| Celera Genomics | Board of Directors | Current |
| Applied Biosystems Group | Board of Directors | Current |
| Applied Biosystems Group | Committee Member | Current |
| Olink | Committee Member | Current |
| The Stanley Works | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Celera Genomics | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Gordon and Betty Moore Foundation | Chief Program Officer and General Counsel | Current |
| Celera Genomics | Board of Directors | Current |
| Brobeck, Phleger & Harrison | Partner | Former |
| Gordon and Betty Moore Foundation | General Counsel | Former |
| Yale University | Undergraduate Degree | Former |
Executive News
-
Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors
-
Strategic Product Development Expert to Educate Utah Technology Company Executives
-
UPDATE 1-Leerink Swann raises Boston Scientific to outperform
Industry Transcripts by Seeking Alpha
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
-
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about JAV
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
on Nov 09, 2009about ALXA
Glass Door
Celera Group
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

